# Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

> **NCT01021956** · PHASE2 · TERMINATED · sponsor: **Steba Biotech S.A.** · enrollment: 10 (actual)

## Conditions studied

- Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** STAKEL

## Key facts

- **NCT ID:** NCT01021956
- **Lead sponsor:** Steba Biotech S.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2012-05
- **Final completion:** 2014-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Retinal vascular occlusion in 2 patients
- **Last updated:** 2018-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01021956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01021956, "Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01021956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*